Helmut Drexler

Active 1984–2016

115
Papers
45,121
Citations
101
h-index
115
i10-index

Citations

Citations per year for Helmut Drexler1960: 1 citations1964: 1 citations1971: 1 citations1986: 1 citations1989: 1 citations1990: 3 citations1991: 2 citations1992: 3 citations1993: 11 citations1994: 21 citations1995: 34 citations1996: 47 citations1997: 70 citations1998: 75 citations1999: 114 citations2000: 142 citations2001: 155 citations2002: 183 citations2003: 260 citations2004: 357 citations2005: 486 citations2006: 594 citations2007: 595 citations2008: 607 citations2009: 575 citations2010: 594 citations2011: 603 citations2012: 528 citations2013: 469 citations2014: 353 citations2015: 352 citations2016: 275 citations2017: 265 citations2018: 237 citations2019: 849 citations2020: 817 citations2021: 657 citations2022: 507 citations2023: 361 citations2024: 484 citations2025: 206 citations2026: 3 citations1961–1963: no citations, so these years are not shown1965–1970: no citations, so these years are not shown1972–1985: no citations, so these years are not shown1987–1988: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,851 citing papers, 24% of this breakdownGermany: 1,437 citing papers, 8.9% of this breakdownUnited Kingdom: 1,256 citing papers, 7.8% of this breakdownItaly: 980 citing papers, 6.1% of this breakdownChina: 897 citing papers, 5.6% of this breakdownNetherlands: 642 citing papers, 4% of this breakdownCanada: 552 citing papers, 3.4% of this breakdownJapan: 548 citing papers, 3.4% of this breakdownFrance: 499 citing papers, 3.1% of this breakdownAustralia: 459 citing papers, 2.9% of this breakdownSpain: 398 citing papers, 2.5% of this breakdownSwitzerland: 382 citing papers, 2.4% of this breakdown
0%24%Other 25.9%

Fields

  • Medicine74.1%
  • Biochemistry, Genetics and Molecular Biology15.1%
  • Immunology and Microbiology4.8%
  • Nursing1.4%
  • Engineering1.1%
  • Neuroscience1.1%
  • Other2.4%

Topics

  • Heart Failure Treatment and Management3.7%
  • Nitric Oxide and Endothelin Effects3.2%
  • Cardiovascular Health and Disease Prevention3.1%
  • Cardiac Fibrosis and Remodeling3%
  • Cardiovascular Function and Risk Factors2.7%
  • Mesenchymal stem cell research2.1%
  • Other82.2%

Coauthors

All papers

Open in search
  1. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency

    Authors: , , , , , , , , , , , , , , , - New England Journal of Medicine 2009 cited by 2,055

  2. Targeted Anticytokine Therapy in Patients With Chronic Heart Failure

    Authors: , , , , , , , , , , , , , , , , , , , - Circulation 2004 cited by 1,230

  3. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery

    Authors: , , , , , , , , , , , , - Journal of the American College of Cardiology 2002 cited by 4,581

  4. The Transforming Growth Factor-β Superfamily Member Growth-Differentiation Factor-15 Protects the Heart From Ischemia/Reperfusion Injury

    Authors: , , , , , , , , , , , , - Circulation Research 2006 cited by 641

  5. From Vulnerable Plaque to Vulnerable Patient

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wolfgang Köenig, Robert A. Lodder, Keith L. March, Jasenka Demirovic, Mohamad Navab, Silvia G. Priori, Mark D. Rekhter, Raymond D. Bahr, Scott M. Grundy, Roxana Mehran, Antonio Colombo, Eric Boerwinkle, Christie M. Ballantyne, William Insull, Robert S. Schwartz, Robert A. Vogel, Patrick W. Serruys, Göran K. Hansson, David P. Faxon, Sanjay Kaul, Helmut Drexler, Philip Greenland, James E. Muller, Renu Virmani, Paul M. Ridker, Douglas P. Zipes, Prediman K. Shah, James T. Willerson - Circulation 2003 cited by 2,671

  6. Prognostic Utility of Growth Differentiation Factor-15 in Patients With Chronic Heart Failure

    Authors: , , , , , , , , , , , - Journal of the American College of Cardiology 2007 cited by 494

  7. A Cathepsin D-Cleaved 16 kDa Form of Prolactin Mediates Postpartum Cardiomyopathy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Cell 2007 cited by 906

  8. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial

    Authors: , , , , , , , , , , - The Lancet 2009 cited by 645

  9. Serial Measurement of Growth-Differentiation Factor-15 in Heart Failure

    Authors: , , , , , , , , , - Circulation 2010 cited by 313

  10. Role of oxidative stress in atherosclerosis

    Authors: , , , , - The American Journal of Cardiology 2003 cited by 1,265

  11. Impact of Interleukin-6 on Plaque Development and Morphology in Experimental Atherosclerosis

    Authors: , , , , , , , , , , , - Circulation 2004 cited by 341

  12. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)

    Authors: , , , , , , , , , , , , , , , , , , - European Heart Journal 2005 cited by 2,262

  13. Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation Acute Coronary Syndrome

    Authors: , , , , , , , , , , , , , - Circulation 2007 cited by 376

  14. The myocardial JAK/STAT pathway: From protection to failure

    Authors: , , , , - Pharmacology & Therapeutics 2008 cited by 352

  15. Expression of Angiotensin II and Interleukin 6 in Human Coronary Atherosclerotic Plaques

    Authors: , , , , , , , , - Circulation 2000 cited by 644

  16. Endothelial-Vasoprotective Effects of High-Density Lipoprotein Are Impaired in Patients With Type 2 Diabetes Mellitus but Are Improved After Extended-Release Niacin Therapy

    Authors: , , , , , , , , , , , , , , , , , - Circulation 2009 cited by 405

  17. Monitoring of Bone Marrow Cell Homing Into the Infarcted Human Myocardium

    Authors: , , , , , , , , - Circulation 2005 cited by 933

  18. Fluid status telemedicine alerts for heart failure: a randomized controlled trial

    Authors: , , , , , , , , , , , , , - European Heart Journal 2016 cited by 250

  19. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial

    Authors: , , , , , , , , , , , , , - The Lancet 2004 cited by 2,186

  20. Circulating Concentrations of Growth-Differentiation Factor 15 in Apparently Healthy Elderly Individuals and Patients with Chronic Heart Failure as Assessed by a New Immunoradiometric Sandwich Assay

    Authors: , , , , , , , , , - Clinical Chemistry 2006 cited by 284

  21. Vascular Oxidative Stress and Endothelial Dysfunction in Patients With Chronic Heart Failure

    Authors: , , , , , , , , - Circulation 2002 cited by 516

  22. Critical Role of the NAD(P)H Oxidase Subunit p47 phox for Left Ventricular Remodeling/Dysfunction and Survival After Myocardial Infarction

    Authors: , , , , , , , , , , - Circulation Research 2007 cited by 206

  23. Continuous Glycoprotein-130–Mediated Signal Transducer and Activator of Transcription-3 Activation Promotes Inflammation, Left Ventricular Rupture, and Adverse Outcome in Subacute Myocardial Infarction

    Authors: , , , , , , , , , , , - Circulation 2010 cited by 167

  24. Evaluation of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb ischemia

    Authors: , , , , , - Nature Protocols 2009 cited by 403